Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F. Wang, Rui‐Hua Xu, Xiaoli Wei et al.|Annals of Oncology|2019Cited by 475
Physiological sensing system integrated with vibration sensor and frequency gel dampers inspired by spiderJianren Huang, Lunhui Guan, Qirui Wu et al.|Materials Horizons|2023Cited by 29
RNU12 inhibits gastric cancer progression via sponging miR-575 and targeting BLIDShaoli Wang, Xiandong Lin|Scientific Reports|2023Cited by 3